Diabetologia

Diabetologia Journal

Publication venue for

Evidence of significant reduction in pain and sensory symptoms of diabetic neuropathy with 10kHz spinal cord stimulation: 24-month RCT outcomes. 65:S28-S29. 2022
A real-world retrospective study evaluating glycaemic control with glucagon-like peptide-1 receptor agonists or basal insulin in type 2 diabetes in the UK. 62:S420-S421. 2019
Impact of disease duration and beta cell reserve on the efficacy of iGlarLixi in patients with type 2 diabetes: the LixiLan-G trial. 62:S427-S427. 2019
Liraglutide as add-on to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes: a 26-week, randomised, double-blind, placebo-controlled trial. 62:S371-S372. 2019
Predictive modelling suggests subgroup effects for severe hypoglycaemia in type 2 diabetes patients treated with Gla-300 vs IDeg: the LIGHTNING study. 62:S437-S438. 2019
Switching to iGlarLixi vs continuation of glucagon-like peptide-1 receptor agonist in inadequately controlled type 2 diabetes: the randomised LixiLan-G trial. 62:S427-S428. 2019
Impact of type 2 diabetes duration on response to iGlarLixi vs iGlar: a subanalysis of LixiLan-L. 61:S386-S386. 2018
Total and severe hypoglycaemia is reduced with use of inhaled Technosphere Insulin (TI) relative to insulin aspart in type 1 diabetes. 61:S29-S29. 2018
Characteristics and outcomes of type 2 diabetes patients titrated to 60U/day with insulin glargine/lixisenatide fixed-ratio combination vs insulin in LixiLan-L. 60:S371-S371. 2017
Clinical benefit of simultaneous initiation of basal insulin and GLP-1 in patients with type 2 diabetes and elevated HbA(1c) as supported by real-world evidence. 60:S310-S310. 2017
Impact of time to basal insulin initiation on glycaemic control in type 2 diabetes patients: an electronic medical record database analysis. 59:S441-S441. 2016
Differential effects of GLP-1 receptor agonists on 24-hour averaged heart rate in healthy volunteers and patients with type 2 diabetes. 58:S8-S8. 2015
Distribution of weight loss with canagliflozin in patients with type 2 diabetes mellitus over 104 weeks. 58:S354-S355. 2015
Effects of canagliflozin on body weight and relationship to HbA(1c) and blood pressure changes in patients with type 2 diabetes. 58:1183-1187. 2015
Reduced hypoglycaemia is observed with inhaled insulin versus subcutaneous insulin aspart in patients with type 1 diabetes mellitus. 58:S449-S450. 2015
Better glycaemic control and less weight gain with once weekly dulaglutide vs bedtime insulin glargine, both combined with thrice daily lispro, in type 2 diabetes (AWARD-4). 57:S23-S24. 2014
Characteristics of patients with type 2 diabetes mellitus (T2DM) on basal insulin who do not achieve glycaemic goals. 57:S54-S54. 2014
Glycaemic efficacy of canaglilozin by baseline HbA1c and known duration of type 2 diabetes mellitus. 57:S344-S344. 2014
Hypoglycaemia in people with type 2 diabetes achieving vs not achieving HbA1c target levels over 4 years in routine clinical practice: analysis of the CREDIT study. 57:S399-S400. 2014
IDegLira, a combination of insulin degludec and liraglutide, enables patients with type 2 diabetes to reach target glycaemic control faster than its individual components alone. 57:S339-S339. 2014
Relationship between changes in postprandial glucagon, patient characteristics, and response to lixisenatide as add-on to oral antidiabetics. 57:S344-S344. 2014
Unmet needs in HbA1c goal achievement (< 7.0%) by patients with type 2 diabetes mellitus treated with basal insulin: pooled randomised controlled trial data and real-world clinical practice data. 57:S394-S394. 2014
Canagliflozin lowers HbA(1c) and blood pressure through weight loss-independent and weight loss-associated mechanisms. 56:S379-S379. 2013
Insulin degludec is highly efficacious regardless of diabetes duration or body mass index: a cross-trial evaluation. 55:S378-S379. 2012
Insulin degludec does not compromise efficacy or safety when given in a flexible once-daily dosing regimen compared to insulin glargine once daily at the same time each day in type 2 diabetes. 54:S53-S53. 2011
Insulin degludec in a flexible daily dosing regimen provides similar glycaemic control without increasing rates of hypoglycaemia compared to dosing the same time daily in type 2 diabetes. 54:S423-S423. 2011
Efficacy and goal attainment with insulin glargine vs comparators. 53. 2010
Patient-centered outcomes and glycaemic variability in type 1 and type 2 diabetes: a cross-over trial of insulin glargine plus glulisine vs premix analogue insulin. 53. 2010
Predictors of continuous glucose monitoring (CGM) variability and associations with patient satisfaction and health perceptions in insulin-treated diabetes. 53. 2010
A switch from twice-daily exenatide to once-daily liraglutide further improves glycaemic control in patients with type 2 diabetes on oral agents. 52:S7-S8. 2009
Diabetes treatment satisfaction in a 20-week, randomized, controlled trial (TITRATE STUDY). 52:S381-S381. 2009
Glycaemic outcomes 1 year after initiation of insulin glargine or detemir in type 2 diabetes in the US. 52:S350-S351. 2009
Effect of the GLP-1 analogueliraglutide on glycaemic control and weight reduction in patients on metformin and rosiglitazone: a randomized double-blind placebo-controlled trial. 51:S359-S359. 2008
Vildagliptin is as effective as TZDs in metformin failures: results of GALIANT - a primary care diabetes study. 51:S366-S366. 2008

International Standard Serial Number (ISSN)

0012-186X